Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

EyePoint

5.01
+0.13502.77%
Post-market: 5.020.0147+0.29%17:58 EDT
Volume:4.12M
Turnover:20.99M
Market Cap:431.49M
PE:-1.33
High:5.29
Open:4.98
Low:4.96
Close:4.87
52wk High:19.11
52wk Low:3.95
Shares:86.21M
Float Shares:60.67M
Volume Ratio:0.46
T/O Rate:6.80%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7642
EPS(LYR):-3.1667
ROE:-148.70%
ROA:-74.85%
PB:2.59
PE(LYR):-1.58

Loading ...

OverviewCompanyNewsFilings

EyePoint price target lowered to $8 from $30 at Jefferies

TIPRANKS
·
Aug 18

JPMorgan Downgrades EyePoint Pharmaceuticals to Neutral From Overweight

MT Newswires Live
·
Aug 17

EyePoint downgraded to Neutral from Overweight at JPMorgan

TIPRANKS
·
Aug 17

U.S. Stocks on the MOVE - Sunrun, JetBlue Airways, Dell Technologies

Reuters
·
Aug 17

Top Midday Stories: Nvidia Investing $1.5 Billion in SB Energy; L3Harris Names Sam Mehta as CEO, Replacing Christopher Kubasik

MT Newswires Live
·
Aug 17

EyePoint Stock Craters 71% After Drug Trial Failure. it May be an Overreaction.

Dow Jones
·
Aug 17

EyePoint Down over 70%, on Pace for Record Percent Decrease

Dow Jones
·
Aug 17

EyePoint Reports Pivotal Phase 3 LUGANO Trial Results

TIPRANKS
·
Aug 17

Rival Ocular Therapeutix Shares up 8%

THOMSON REUTERS
·
Aug 17

Morning Movers: EyePoint plummets following LUGANO trial results

TIPRANKS
·
Aug 17

EyePoint is Maintained at Buy by Chardan Capital

Dow Jones
·
Aug 17

EyePoint Tumbles After Experimental Eye Drug Misses Main Goal in Late-Stage Study

Reuters
·
Aug 17

EyePoint Eye Drug Misses Main Goal in Late-Stage Trial

Reuters
·
Aug 17

EyePoint Says Phase 3 Lugano Trial of Duravyu in Wet AMD Misses Primary Endpoint

Reuters
·
Aug 17

EyePoint - Primary Endpoint not Achieved in Full Dataset Due to Asymmetric Cohort

THOMSON REUTERS
·
Aug 17

EyePoint - Lucia Phase 3 Topline Data Expected Q4 2026; FDA Nda Submission Planned 1H 2027

THOMSON REUTERS
·
Aug 17

EyePoint Announces Topline Data from Lugano, the First of Two Pivotal Phase 3 Clinical Trials for Duravyu™ 2.7Mg in Wet Amd

THOMSON REUTERS
·
Aug 17

EyePoint - Duravyu Achieves 42% Reduction in Treatment Burden vs Aflibercept

THOMSON REUTERS
·
Aug 17

EyePoint - Duravyu Non-Inferior to Aflibercept in Ad Hoc Analysis Excluding 4% Asymmetric Cohort

THOMSON REUTERS
·
Aug 17

EyePoint - Duravyu Observed to be Safe and Well Tolerated with Repeat Dosing

THOMSON REUTERS
·
Aug 17
More